Cannabinoids in 2026: Policy Is Sprinting. The Evidence Is Walking.

Cannabinoid policy has moved faster in the past 90 days than at any point in the last 50 years. The Department of Justice reclassified FDA-approved cannabis products and state-licensed medical marijuana from Schedule I to Schedule III on April 23. The Federal Register notice was published April 28. A full-rescheduling hearing — which would extend to adult-use cannabis — is set for June 29. Section 280E tax disallowance, the IRS rule that has crushed the unit economics of state-legal medical operators for a decade, lifts for qualifying medical activity. Research constraints loosen. The whole field exhales.

At the same time, the cannabinoid evidence base — the actual science of what cannabis does to people, for whom, in what doses, with what consequence — is approximately where it was three years ago. Two recent syntheses make the gap impossible to ignore.

Lens 1 — Science: a 57-trial network meta-analysis of CUD treatments lands almost simultaneously with the policy move

A network meta-analysis published in The Lancet Psychiatry (with secondary coverage in Medscape) pulled together 57 randomized controlled trials of cannabis use disorder treatment: 21 psychosocial trials covering 3,157 patients and 36 pharmacotherapy trials covering 3,120 patients, in people 16 and older. The findings, distilled honestly: DBT/ACT, MET-CBT, and MET-CBT plus contingency management all show meaningful reductions in cannabis use frequency. The certainty of the evidence is low to very low. No pharmacotherapy is recommended for routine use. There remains, in May 2026, zero FDA-approved medication for cannabis use disorder.

Separately, a secondary analysis published this month reports that roughly 31% of people meeting criteria for CUD also meet criteria for major depressive disorder — a comorbidity rate high enough that any CUD treatment plan that ignores depression is, by definition, an incomplete plan.

Lens 2 — Policy: Schedule III is real, but it is narrower than the news cycle suggests

The DOJ order does not legalize anything. It moves FDA-approved cannabis products (a small category, dominated by Epidiolex) and state-licensed medical cannabis from Schedule I to Schedule III. Recreational use remains federally illegal. The big near-term effects are tax (§280E lifts), banking (modestly improved), and research (modestly easier). The big near-term non-effects are: this does not change FDA-approved indications, it does not change state-by-state medical access, and it does not create any new approved treatment for any condition. The June 29 hearing is the next inflection point worth watching. Notice of participation was due May 28.

Lens 3 — Social-cultural: the population using cannabis medicinally is, in large part, using it for conditions the evidence does not support

The most uncomfortable finding of the Lancet Psychiatry work, from a public-health standpoint, is the mismatch between why people say they use medical cannabis and what the trials show. Anxiety, depression, and PTSD are the conditions most commonly cited by medical cannabis users. They are also three of the conditions where the network meta-analysis finds the weakest or absent randomized evidence — including zero RCTs supporting cannabis for depression.

This is not a moral statement. It is a statement about a treatment context where personal experience, cultural availability, and clinical evidence have diverged. People in recovery from other substances are over-represented in the medical-cannabis-for-anxiety cohort. That deserves to be named without judgment, and engaged honestly.

Recent developments

• April 23–28, 2026 — DOJ partial Schedule III rescheduling order signed and published in the Federal Register.
• May 2026 — Lancet Psychiatry NMA of CUD treatments; secondary CUD-MDD comorbidity analysis.
• June 29, 2026 — DEA/DOJ administrative hearing scheduled for full rescheduling.

Where the field disagrees

There is honest, ongoing disagreement in the field about (1) whether high-potency THC products available in adult-use markets contribute to CUD prevalence at a population level (mounting evidence: yes), (2) whether full rescheduling will, on net, expand or contract access to appropriate medical use, and (3) whether the absence of FDA-approved CUD pharmacotherapy reflects the difficulty of the science or the lack of commercial incentive when the substance is widely available legally in many states. None of these have clean answers. Anyone telling you they do is selling something.

Why this matters for people in recovery

If you are working on your cannabis use, the most evidence-informed plan in 2026 is a behavioral one: motivational enhancement, cognitive-behavioral therapy, and — where available — contingency management. If depression is in the picture, treat the depression too. If you are reading about Schedule III and wondering if anything changed for you personally, the honest answer is: very little, this month. The work of getting better is the same work it was the day before the order was signed.

The work of getting better is the same work it was the day before the order was signed.

Need help right now?

• 988 Suicide & Crisis Lifeline
• Find treatment: Rize Recovery
• Cannabis quit support: /r/leaves (community), Marijuana Anonymous